These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21142607)

  • 1. The impact of retention in early HIV medical care on viro-immunological parameters and survival: a statewide study.
    Tripathi A; Youmans E; Gibson JJ; Duffus WA
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):751-8. PubMed ID: 21142607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retention in care: a challenge to survival with HIV infection.
    Giordano TP; Gifford AL; White AC; Suarez-Almazor ME; Rabeneck L; Hartman C; Backus LI; Mole LA; Morgan RO
    Clin Infect Dis; 2007 Jun; 44(11):1493-9. PubMed ID: 17479948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of time to enter medical care after a new HIV diagnosis: a statewide population-based study.
    Tripathi A; Gardner LI; Ogbuanu I; Youmans E; Stephens T; Gibson JJ; Duffus WA
    AIDS Care; 2011 Nov; 23(11):1366-73. PubMed ID: 22022847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linkage and retention in care and the time to HIV viral suppression and viral rebound - New York City.
    Robertson M; Laraque F; Mavronicolas H; Braunstein S; Torian L
    AIDS Care; 2015; 27(2):260-7. PubMed ID: 25244545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
    Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
    AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome.
    Onen NF; Overton ET; Presti R; Blair C; Powderly WG; Mondy K
    HIV Med; 2009 Aug; 10(7):439-46. PubMed ID: 19459993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus.
    Torian LV; Wiewel EW; Liu KL; Sackoff JE; Frieden TR
    Arch Intern Med; 2008 Jun; 168(11):1181-7. PubMed ID: 18541826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One year survival of HIV-infected veterans with CD4 < 100 cells/mm3: data from a veteran cohort.
    Breaux K; Gadde S; Graviss EA; Rodriguez-Barradas MC
    AIDS Care; 2010 Jul; 22(7):886-94. PubMed ID: 20635253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in HIV manifestations at presentation to care and continuity of care among HIV-infected persons in Taiwan.
    Ko NY; Lai YY; Liu HY; Ko WC; Chang CM; Lee NY; Chen PL; Wu CJ; Lee HC
    AIDS Care; 2011 Oct; 23(10):1254-63. PubMed ID: 21939404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How late is too late? Timeliness to scheduled visits as an antiretroviral therapy adherence measure in Nairobi, Kenya and Lusaka, Zambia.
    Blacher RJ; Muiruri P; Njobvu L; Mutsotso W; Potter D; Ong'ech J; Mwai P; Degroot A; Zulu I; Bolu O; Stringer J; Kiarie J; Weidle PJ
    AIDS Care; 2010 Nov; 22(11):1323-31. PubMed ID: 20711886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between pharmacy medication refill-based adherence rates and cd4 count and viral-load responses: A retrospective analysis in treatment-experienced adults with HIV.
    Townsend ML; Jackson GL; Smith R; Wilson KH
    Clin Ther; 2007 Apr; 29(4):711-6. PubMed ID: 17617294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to first annual HIV care visit and associated factors for patients in care for HIV infection in 10 US cities.
    Sullivan PS; Juhasz M; McNaghten AD; Frankel M; Bozzette S; Shapiro M
    AIDS Care; 2011 Oct; 23(10):1314-20. PubMed ID: 21939408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
    Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
    Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users.
    Wood E; Kerr T; Zhang R; Guillemi S; Palepu A; Hogg RS; Montaner JS
    HIV Med; 2008 Aug; 9(7):503-7. PubMed ID: 18484977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of HIV-1 viral load and CD4 lymphocyte count as determinants of progression to AIDS and survival].
    Romeu J; Balagué M; Ruiz L; Marfil S; Puig T; Arnó A; Veny A; Tural C; Sirera G; Clotet B
    Med Clin (Barc); 1998 Jun; 110(20):761-7. PubMed ID: 9666416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.